1型糖尿病青少年他汀类和ACE抑制剂辅助治疗期间的用药依从性
研究纳入443例1型糖尿病青少年,在AdDIT试验中接受ACE抑制剂和他汀类口服药治疗2-4年,每3个月用药物事件监测系统(MEMS)和药片计数评估依从性。MEMS中位依从性80.2%,药片计数85.7%,依从性随时间下降,依从性≥75%者从84%降至53%。年龄、血糖控制和国别与依从性相关。
要点
- MEMS中位依从性80.2%,药片计数中位依从性85.7%。
- 依从性≥75%的受试者比例从84%降至53%。
- 年龄较大和基线血糖控制欠佳预测试验期间依从性较低。
核心结论
- 临床试验期间对ACE抑制剂和他汀类的总体依从性良好,但依从性随时间明显下降。
- 基线年龄较大和血糖控制欠佳预测试验期间依从性较低,依从性降低在随后退出研究的受试者中更常见。
研究设计与样本
- 443例1型糖尿病青少年被纳入Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial(AdDIT),接受ACE抑制剂和他汀类两种口服药及其组合或安慰剂治疗2-4年。
- 每3个月用药物事件监测系统(MEMS)和药片计数评估依从性。
主要发现
- 试验期间MEMS中位依从性为80.2%(四分位距63.6-91.8),药片计数中位依从性为85.7%(72.4-92.9)。
- MEMS依从性从首次访视的92.9%降至试验结束时的76.3%,药片计数依从性从96.3%降至79.0%。
- 依从性≥75%的受试者比例从84%降至53%。
- MEMS与药片计数依从性之间相关性良好(r=0.82,P<0.001)。
- 与依从性相关的因素为年龄、血糖控制和国别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Suboptimal adherence to insulin treatment is a main issue in adolescents with type 1 diabetes. However, to date, there are no available data on adherence to adjunct noninsulin medications in this population. Our aim was to assess adherence to ACE inhibitors and statins and explore potential determinants in adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS: There were 443 adolescents with type 1 diabetes recruited into the Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT) and exposed to treatment with two oral drugs-an ACE inhibitor and a statin-as well as combinations of both or placebo for 2-4 years. Adherence was assessed every 3 months with the Medication Event Monitoring System (MEMS) and pill count. RESULTS: Median adherence during the trial was 80.2% (interquartile range 63.6-91.8) based on MEMS and 85.7% (72.4-92.9) for pill count. Adherence based on MEMS and pill count dropped from 92.9% and 96.3%, respectively, at the first visit to 76.3% and 79.0% at the end of the trial. The percentage of study participants with adherence ≥75% declined from 84% to 53%. A good correlation was found between adherence based on MEMS and pill count (r = 0.82, P < 0.001). Factors associated with adherence were age, glycemic control, and country. CONCLUSIONS: We report an overall good adherence to ACE inhibitors and statins during a clinical trial, although there was a clear decline in adherence over time. Older age and suboptimal glycemic control at baseline predicted lower adherence during the trial, and, predictably, reduced adherence was more prevalent in subjects who subsequently dropped out.
引用
- Niechciał E, Acerini CL, Chiesa ST, et al. Medication Adherence During Adjunct Therapy With Statins and ACE Inhibitors in Adolescents With Type 1 Diabetes. Diabetes Care. 2020. PMID: 32108022. doi:10.2337/dc19-0884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。